EUVIMEDEUVIMED entdecken
Crossref

Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN ‐ FRT recommendations

T Torres iD, N C Brembilla, B King, R Chovatiya iD, R B Warren, C Flohr iD, C Vestergaard, A D Irvine iD, J M Carrascosa iD, J T Maul iD, C H Smith iD, R G Langley und 6 weitere

Journal of the European Academy of Dermatology and Venereology · 10.08.2026

DOI: 10.1111/jdv.70634 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 10.08.2026. Verfasst von T Torres und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Centro Académico Clínico, ICBAS/Santo António, Porto, Portugal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 132 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The expanding use of biologic and oral targeted therapies has transformed the management of psoriasis and atopic dermatitis. These agents are increasingly prescribed to patients with current malignancy, a history of malignancy or an increased cancer risk, populations typically excluded from clinical trials. In the absence of robust long‐term safety data, clinicians often rely on real‐world evidence to inform treatment decisions.

Objectives

To review the evidence regarding malignancy risk associated with biologic and oral targeted therapies used in psoriasis and atopic dermatitis and to provide expert consensus recommendations for patients with current malignancy, previous malignancy or increased risk of malignancy.

Methods

We describe the physiological roles of key immune pathways targeted in psoriasis and atopic dermatitis, as well as in cancer immunosurveillance, tumour progression and immune escape. We then summarize evidence from randomized controlled trials regarding the risk of de novo malignancy, followed by a synthesis of real‐world data addressing cancer recurrence and progression in patients treated with biologic and oral targeted therapies.

Results

Available evidence suggests that the overall malignancy risk associated with most biologic and oral targeted therapies used in psoriasis and atopic dermatitis is low, although differences between therapeutic classes may exist. Real‐world data remain limited for several therapeutic classes and in patients with active or previous malignancy.

Conclusions

Based on the available evidence, we present consensus‐based recommendations developed by a multidisciplinary expert panel convened by the Skin Inflammation & Psoriasis International Network–Fondation René Touraine (SPIN‐FRT). These recommendations aim to support treatment decisions by balancing disease control with potential cancer‐related risks while highlighting key evidence gaps.

Schlagwörter

Stichwörter der Autor:innen

IL‐13 inhibitorsIL‐17 inhibitorsIL‐23 inhibitorsIL‐4α; inhibitorJAK inhibitorsPDE4 inhibitorsatopic dermatitisbDMARDscDMARDscancerconsensusmalignancypsoriasisrecommendation

Autor:innen und Institutionen

  • Department of Dermatology, Centro Académico Clínico, ICBAS/Santo António, Porto, Portugal.
  • Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.
  • Division of Dermatology and Venereology, University Hospitals of Geneva, Geneva, Switzerland.
  • Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Dermatology Physicians of Connecticut, Fairfield, Connecticut, USA.
  • Rosalind Franklin University of Medicine and Science Chicago Medical School, North Chicago, Illinois, USA.

ORCID-Profile: T Torres, R Chovatiya, C Flohr, A D Irvine, J M Carrascosa, J T Maul, C H Smith, V Sibaud, L Puig

Zitieren

APA

Torres, T., Brembilla, N. C., King, B., Chovatiya, R., Warren, R. B., Flohr, C., Vestergaard, C., Irvine, A. D., Carrascosa, J. M., Maul, J. T., Smith, C. H., Langley, R. G., Cortés, J., Sibaud, V., Thaçi, D., Boehncke, W. H., Spuls, P., & Puig, L. (2026). Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN ‐ FRT recommendations. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70634

Vancouver

Torres T, Brembilla NC, King B, Chovatiya R, Warren RB, Flohr C, et al. Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN ‐ FRT recommendations. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70634

BibTeX
@article{Torres2026,
  author = {Torres, T and Brembilla, N C and King, B and Chovatiya, R and Warren, R B and Flohr, C and Vestergaard, C and Irvine, A D and Carrascosa, J M and Maul, J T and Smith, C H and Langley, R G and Cortés, J and Sibaud, V and Thaçi, D and Boehncke, W H and Spuls, P and Puig, L},
  title = {Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN ‐ FRT recommendations},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70634}
}
Kostenlos starten →